J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Sarcoidosis mimicking recurrent lymphoma.
Wei Li,Karen P. Holdeman,Javier A. Laurini,Philip J. Bierman,Julie M. Vose,Robert G. Bociek,James O. Armitage +6 more
TL;DR: Although it appeared that the patient had relapsed, a decision was made to not institute therapy without histological proof of recurrent lymphoma, and the patient has remained in remission from lymphoma for more than 4 years.
Journal ArticleDOI
Challenges in Opening and Enrolling Patients in Clinical Trials.
TL;DR: Some of the identified issues that are slowing the process of cancer clinical trials, such as conservatively interpreted guidelines by pharmaceutical companies and contract research organizations; overprotective language for contracts; and patient protections by health systems and universities are discussed.
Journal ArticleDOI
Autologous Transplant Event-Free Survival (EFS) Following Failure of CHOP-Rituximab (CHOP-R) for Diffuse Large B-Cell Lymphoma (DLBCL) Is the Same as the EFS Following Failure of CHOP Alone.
TL;DR: Concerns of increased resistance of DLBCL following failure of CHOP-R and the inability to salvage those patients with high-dose chemotherapy and autologous stem cell transplantation have been raised.
Journal ArticleDOI
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Shantaram S. Joshi,Michael R. Bishop,Michael R. Bishop,James C. Lynch,Stefano R. Tarantolo,Sunil Abhyankar,P. J. Bierman,Julie M. Vose,R. B. Geller,Joseph P. McGuirk,James M. Foran,Robert G. Bociek,Abdul Hadi,S. D. Day,James O. Armitage,Anne Kessinger,Z. S. Pavletic +16 more
TL;DR: There were no significant immunological or alterations in clinical benefit of post-transplant G-CSF administration in T-replete allotransplant recipients.
Journal Article
Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
Avyakta Kallam,Julie M. Vose +1 more
TL;DR: In this paper, a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent, was presented.